Epic Sciences to present at Personalized Medicine World Conference 2015 on the use of circulating tumor cells as cancer biomarkers.
Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which is taking place at the Computer History Museum in Mountain View, Calif. on January 26-28, 2015.
Dr. Prahalad will give a presentation entitled, “CTCs Come of Age as Biomarkers.” Last year, Epic Sciences was a finalist in the PMWC’s Most Promising Company Award Competition.
The details of the presentation are as follows:
- Date: Tuesday, January 27, 2015
- Track 1: Applying Complementary Technologies Towards Biomarker Discovery
- Time: 3:45 PM PST
Co-hosted with Stanford Health Care and Oracle in Silicon Valley, PMWC 2015 will gather close to 1,000 multidisciplinary attendees and key stakeholders from the business, government, healthcare delivery, research and technology arenas to examine the advances and challenges of personalized medicine through a practical lens.
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., firstname.lastname@example.org,+1.858.344.8091